A synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier. or A substance that is being studied in the treatment of cancer. It is a matrix metalloproteinase inhibitor and belongs to the family of drugs called angiogenesis inhibitors. Also called AG3340.